Ontario Framework for Funding Drugs for Rare Diseases
Doug Coyle (U of Ottawa) 3:00–4:00 PM, Room 3340, 2405 Wesbrook Mall Details
Work in Progress Seminar
Dr. Nadia Khan 12:00–1:00 PM, Hurlburt Auditorium, St. Paul’s Details
E-Mental Health Conference
Early bird registration for the 2015 E-Mental Health Conference ends November 30 ($65). The conference will take place January 17 and 18 at the Child and Family Research Institute (938 W 28 Avenue) in Vancouver.
Melissa Pak (left) and Dr. Karin Humphries in front of their poster at the American Heart Association’s 2014 Scientific Sessions.
CHÉOS at American Heart Association 2014
CHÉOS Scientists were in Chicago this month presenting their research at both the American Heart Association’s (AHA) 2014 Scientific Sessions and the Resuscitation Science Symposium.At the Scientific Sessions, which took place from November 15–19, BC Centre for Improved Cardiovascular Health Research (ICVHealth) Research Manager Melissa Pak discussed her team’s poster on “Impact of Patient Transfers on Outcome Evaluations Following Acute Myocardial Infarction.” Also, CHÉOS Scientist and ICVHealth Scientific Director Dr. Karin Humphries gave an oral presentation on “Predictors of Adverse Outcomes Among Patients with Stable Angina and No Obstructive Coronary Artery Disease.”
CHÉOS Scientists Drs. Brian Grunau and Rob Stenstrom also had abstracts accepted at the AHA’s Resuscitation Science Symposium, which took place from November 15–16.
CHÉOS Scientist Dr. Brian Grunau has received a 2014 Resuscitation Science Symposium Young Investigator Award from the AHA for his abstract, “Neurological Outcomes Associated with Duration of Pre-Hospital Resuscitation: Implications for Transport to Invasive Resuscitation.” This award recognizes top-scoring abstracts submitted by investigators who are within the first five years of their appointment. Dr. Grunau was recognized for this award at the AHA’s Resuscitation Science Symposium’s Young Investigator Event on November 14. Congrats!
Clinical and Systems Transformation Project
Providence Health Care interviewed CHÉOS Scientists Drs. Beth Snow (left) and Natalie Henrich, who will be evaluating the effectiveness of the Clinical and Systems Transformation (CST).
The CST is a transformation of clinical practices and systems in health care. A joint undertaking between Providence Health Care, Vancouver Coastal Health and Provincial Health Services Authority, the goal of the CST is to create a new and integrated clinical information system that will allow users to generate, and have immediate access to, more accurate and complete health records and decision support tools.
CHÉOS Scientist Dr. Linda Li was one of the invited presenters at the Arthritis Research Centre of Canada (ARC)’s 2014 Reaching Out With Arthritis Research (ROAR) event, which took place on November 22. This event was an interactive forum for attendees to ask questions and engage in dialogue on how best to shape the future of arthritis research. Dr. Li discussed her research on utilization of activity monitoring tools for people with arthritis in her talk, “Web, Apps and Wearables: Tools for Joint Health?”
Postdoctoral Fellow Opportunity
CHÉOS’ Addictions and Concurrent Disorders Group is looking for a postdoctoral fellow to work in addictions and concurrent disorders research within the UBC Department of Psychiatry.
Applicants for this position should be either a PhD graduate in the last five years, or an MD graduate in psychiatry in the last ten years. The applicant must be involved in a relevant discipline, have strong statistical skills and excellent oral and written communication skills. The candidate should have an interdisciplinary background with a focus on marginalized urban populations, the emerging field of e-Mental Health, and/or online applications. The position is for a one-year term, with possible renewal for an additional year based on results and the availability of funding.
CHÉOS Scientist Dr. Mark Harrison tweeted a photo of the full house at fellow Scientist Dr. Nick Bansback’s presentation at the American College of Rheumatology (ACR) Annual Meeting, which took place in Boston last week. Dr. Bansback’s presentation was titled, “Cost-Effectiveness of Adding Etanercept VS. Sulfasalazine and Hydroxychloroquine to Methotrexate Therapy: A Randomized Noninferiority Trial.”